Cytiva
Cytiva is a global provider of technologies and services that help advance and accelerate the development and manufacture of therapeutics. Previously GE Healthcare Life Sciences, Cytiva’s diverse portfolio includes well-recognized brands such as ÄKTA, Amersham, Biacore, FlexFactory, HyClone, MabSelect, Sefia, Whatman, Xcellerex and Xuri. Cytiva brings speed, efficiency, and capacity to research and manufacturing workflows, enabling the delivery of transformative medicines to patients. Visit cytiva.com for more.
Associated Experts
Job Title: Upstream Applications Specialist Manager
Job Title: Global Product Manager, Bioreactors
Job Title: Strategic Technology Partnerships Leader
Job Title: CTO Upstream
Job Title: Senior Product Manager, Cell and Gene Therap
Associated Content
Achieving Large-Scale GMP Viral Vector Manufacturing
Achieving Large-Scale GMP Viral Vector Manufacturing - [Webinar Available On Demand] As increasing numbers of gene therapies progress through clinical trials and toward commercialization, the need to increase the scale of viral vector manufacturing has become ... Continued
Executing Efficient Scale-up and Large-Scale Viral Vector Manufacturing
In this podcast, we spoke with Margherita Neri, Director of Vector Process Development, Milan Site at AGC Biologics, Andrew Laskowski, Global Product Manager Bioreactors at Cytiva and Andreia Pedregal, Upstream Applications Specialist Manager at Cytiva ... Continued
Visualize Upstream and Downstream Process Intensification Strategies with New Process Intensifier App
Process intensification is an integral part of process design in biomanufacturing . This heightened awareness is due to the increased diversity and complexity of biomolecules and growing pressure to increase the productivity, flexibility and throughput ... Continued
mRNA Vaccines: Current Trends and Perspectives
mRNA therapy is a growing field that is experiencing rapid development and expansion. There are many applications in development that are too numerous to detail in this brief report. The technology offers great benefit and potentials for infectious diseases and personalized medicines due to its advantages in flexibility, cost and speed of development. There are of course still challenges to overcome to fully realize the potential of this technology including lack of experience and knowledge of scaling up mRNA processes, perceived regulatory uncertainties and targeted delivery technologies. The COVID-19 pandemic publicly demonstrated the promise of mRNA therapies, and the future looks bright for this emerging industry....Continued
Reducing Raw Material Variability and Increasing Cell Culture Process Control
How cell culture process variability can be controlled using supplier enabled data management and analytics. Implementing digital biomanufacturing to better control and analyze raw material to reduce variability....Continued